YAP1 and plasma cell myeloma: Interestingly, YAP’s expression and tumoral effects run in parallel to those of WIP: YAP is markedly downregulated in hematological malignancies, including lymphomas, leukemias and multiple myeloma, and is upregulated in cell lines from solid tumors of epithelial origin (Cottini et al., 2014).